{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:27:52Z","timestamp":1794713272614,"version":"4.9.1"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T00:00:00Z","timestamp":1253750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Facial lipoatrophy can be a stigmatizing side effect of antiretroviral (AVR) treatment for HIV\u2010infected patients. We sought to evaluate the long\u2010term efficacy and safety of a new formulation of hyaluronic acid that can be injected in larger amounts and into deeper skin layers during 3 years of follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty patients received injections of Restylane SubQ<jats:sup>\u2122<\/jats:sup>. Refill treatment was offered at 12 and 24 months. Treatment effects were evaluated using ultrasound, the Global Aesthetic Improvement Scale, visual analogue scale (VAS) and the Rosenberg self\u2010esteem scale.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen patients remained at 36 months. Mean (\u00b1 standard deviation) total cutaneous thickness increased from 6 \u00b1 1\u2003mm at baseline to 12 \u00b1 1\u2003mm (<jats:italic>P<\/jats:italic>&lt;0.001) at 36 months. Response rate (total cutaneous thickness &gt;10\u2003mm) was 70%. Fifteen patients classified their facial appearance as very much or moderately improved. VAS increased from 39 \u00b1 25 to 70 \u00b1 20 (<jats:italic>P<\/jats:italic>&lt;0.05) and higher self\u2010esteem scores were reported. Local swelling and tenderness after treatment was common. Persistent papules found in several patients after treatment were removed effectively with hyaluronidase injections. Three patients, treated only at baseline, still had higher total cutaneous thickness scores at 36 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results indicate that a large particle hyaluronic acid formulation is a durable and well\u2010tolerated dermal filler for treating HIV\u2010positive patients with facial lipoatrophy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00761.x","type":"journal-article","created":{"date-parts":[[2009,9,25]],"date-time":"2009-09-25T13:16:57Z","timestamp":1253884617000},"page":"170-177","source":"Crossref","is-referenced-by-count":20,"title":["Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV\u2010positive patients: 3\u2010year follow\u2010up study"],"prefix":"10.1111","volume":"11","author":[{"given":"L","family":"Skeie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Bugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Negaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BM","family":"Bergersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"2441","article-title":"Failure to maintain long\u2010term adherence to highly active antiretroviral therapy","volume":"15","author":"Duran S","year":"2001","journal-title":"the role of lipodystrophy"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540120801926993"},{"key":"e_1_2_7_4_2","first-page":"625","article-title":"Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor\u2010sparing therapy in patients with lipoatrophy","volume":"9","author":"Valantin MA","year":"2008","journal-title":"results from the 96-week randomized ANRS 108 NoNuke Trial"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1310\/hct0906-407"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00305.x"},{"key":"e_1_2_7_7_2","first-page":"67","article-title":"Effect of pioglitazone on HIV\u20101\u2010related lipodystrophy","volume":"13","author":"Slama L","year":"2008","journal-title":"a randomized double-blind placebo-controlled trial (ANRS 113)"},{"key":"e_1_2_7_8_2","first-page":"97","article-title":"Uridine supplementation for the treatment of antiretroviral therapy\u2010associated lipoatrophy","volume":"12","author":"Sutinen J","year":"2007","journal-title":"a randomized, double-blind, placebo-controlled trial"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000222072.37749.5a"},{"key":"e_1_2_7_10_2","first-page":"116","article-title":"Restorative interventions for HIV facial lipoatrophy","volume":"10","author":"Carey D","year":"2008","journal-title":"AIDS Rev"},{"key":"e_1_2_7_11_2","first-page":"923","article-title":"Treatment of HIV lipoatrophy and lipoatrophy of aging with poly\u2010l\u2010lactic acid","volume":"59","author":"Levy RM","year":"2008","journal-title":"a prospective 3-year follow-up study"},{"key":"e_1_2_7_12_2","first-page":"98e","article-title":"Injectable soft\u2010tissue fillers","volume":"118","author":"Eppley BL","year":"2006","journal-title":"clinical overview"},{"key":"e_1_2_7_13_2","first-page":"422","article-title":"Evaluation of the safety of a non\u2010animal stabilized hyaluronic acid (NASHA \u2013 Q\u2010Medical, Sweden) in European countries","volume":"18","author":"Andre P.","year":"2004","journal-title":"a retrospective study from 1997 to 2001"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2008.01039.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00494.x"},{"key":"e_1_2_7_16_2","first-page":"244","article-title":"Hyaluronic acid new formulation","volume":"217","author":"Bechara FG","year":"2008","journal-title":"experience in HIV-associated facial lipoatrophy"},{"key":"e_1_2_7_17_2","volume-title":"Society and the Adolescent Self\u2010Image","author":"Rosenberg M.","year":"1989"},{"key":"e_1_2_7_18_2","first-page":"2471","article-title":"Polylactic acid implants (New\u2010Fill) to correct facial lipoatrophy in HIV\u2010infected patients","volume":"17","author":"Valantin MA","year":"2003","journal-title":"results of the open-label study VEGA"},{"key":"e_1_2_7_19_2","first-page":"397","article-title":"Poly\u2010l\u2010lactic acid injection for HIV\u2010associated facial lipoatrophy","volume":"28","author":"Kates LC","year":"2008","journal-title":"treatment principles, case studies, and literature review"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2006.32190.x"},{"key":"e_1_2_7_21_2","first-page":"1336","article-title":"Safety and efficacy of poly\u2010l\u2010lactic acid injections in persons with HIV\u2010associated lipoatrophy","volume":"32","author":"Mest DR","year":"2006","journal-title":"the US experience"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2007.34027.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.125.12.1623"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2008.34323.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.08.056"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00761.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00761.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T21:38:27Z","timestamp":1698701907000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00761.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00761.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00761.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}